|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Travis WD: Pathology of lung cancer. Clin
Chest Med. 32:669–692. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Schiller JH, Harrington D, Belani CP, et
al: Comparison of four chemotherapy regimens for advanced
non-small-cell lung cancer. N Engl J Med. 346:92–98. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Scagliotti GV, Parikh P, von Pawel J, et
al: Phase III study comparing cisplatin plus gemcitabine with
cisplatin plus pemetrexed in chemotherapy-naive patients with
advanced-stage non-small-cell lung cancer. J Clin Oncol.
26:3543–3551. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hanna N, Shepherd FA, Fossella FV, et al:
Randomized phase III trial of pemetrexed versus docetaxel in
patients with non-small-cell lung cancer previously treated with
chemotherapy. J Clin Oncol. 22:1589–1597. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ciuleanu T, Brodowicz T, Zielinski C, et
al: Maintenance pemetrexed plus best supportive care versus placebo
plus best supportive care for non-small-cell lung cancer: a
randomised, double-blind, phase 3 study. Lancet. 374:1432–1440.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sandler A, Gray R, Perry MC, et al:
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell
lung cancer. N Engl J Med. 355:2542–2550. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hainsworth JD, Fang L, Huang JE, et al:
BRIDGE: an open-label phase II trial evaluating the safety of
bevacizumab + carboplatin/paclitaxel as first-line treatment for
patients with advanced, previously untreated, squamous non-small
cell lung cancer. J Thorac Oncol. 6:109–114. 2011. View Article : Google Scholar
|
|
9
|
Turner NC and Seckl MJ: A therapeutic
target for smoking-associated lung cancer. Sci Transl Med.
2:62ps562010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Soda M, Choi YL, Enomoto M, et al:
Identification of the transforming EML4-ALK fusion gene in
non-small-cell lung cancer. Nature. 448:561–566. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Paez JG, Janne PA, Lee JC, et al: EGFR
mutations in lung cancer: correlation with clinical response to
gefitinib therapy. Science. 304:1497–1500. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lynch TJ, Bell DW, Sordella R, et al:
Activating mutations in the epidermal growth factor receptor
underlying responsiveness of non-small-cell lung cancer to
gefitinib. N Engl J Med. 350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Khuder SA: Effect of cigarette smoking on
major histological types of lung cancer: a meta-analysis. Lung
Cancer. 31:139–148. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rekhtman N, Paik PK, Arcila ME, et al:
Clarifying the spectrum of driver oncogene mutations in
biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS
and presence of PIK3CA/AKT1 mutations. Clin Cancer Res.
18:1167–1176. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kim HS, Mitsudomi T, Soo RA and Cho BC:
Personalized therapy on the horizon for squamous cell carcinoma of
the lung. Lung Cancer. 80:249–255. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cancer Genome Atlas Research Network.
Comprehensive genomic characterization of squamous cell lung
cancers. Nature. 489:519–525. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gold KA, Wistuba II and Kim ES: New
strategies in squamous cell carcinoma of the lung: identification
of tumor drivers to personalize therapy. Clin Cancer Res.
18:3002–3007. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cipriano R, Graham J, Miskimen KL, et al:
FAM83B mediates EGFR- and RAS-driven oncogenic transformation. J
Clin Invest. 122:3197–3210. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Miura A, Honma R, Togashi T, et al:
Differential responses of normal human coronary artery endothelial
cells against multiple cytokines comparatively assessed by gene
expression profiles. FEBS Lett. 580:6871–6879. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Laemmli UK: Cleavage of structural
proteins during the assembly of the head of bacteriophage T4.
Nature. 227:680–685. 1970. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Towbin H, Staehelin T and Gordon J:
Electrophoretic transfer of proteins from polyacrylamide gels to
nitrocellulose sheets: procedure and some applications. Proc Natl
Acad Sci USA. 76:4350–4354. 1979. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ou SH and Zell JA: Carcinoma NOS is a
common histologic diagnosis and is increasing in proportion among
non-small cell lung cancer histologies. J Thorac Oncol.
4:1202–1211. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Noh S and Shim H: Optimal combination of
immunohistochemical markers for subclassification of non-small cell
lung carcinomas: a tissue microarray study of poorly differentiated
areas. Lung Cancer. 76:51–55. 2012. View Article : Google Scholar
|
|
24
|
Ocque R, Tochigi N, Ohori NP and Dacic S:
Usefulness of immu-nohistochemical and histochemical studies in the
classification of lung adenocarcinoma and squamous cell carcinoma
in cytologic specimens. Am J Clin Pathol. 136:81–87. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Conde E, Angulo B, Redondo P, et al: The
use of P63 immunohistochemistry for the identification of squamous
cell carcinoma of the lung. PLoS One. 5:e122092010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bishop JA, Teruya-Feldstein J, Westra WH,
Pelosi G, Travis WD and Rekhtman N: p40 (ΔNp63) is superior to p63
for the diagnosis of pulmonary squamous cell carcinoma. Mod Pathol.
25:405–415. 2012. View Article : Google Scholar
|
|
27
|
Pelosi G, Fabbri A, Bianchi F, et al:
ΔNp63 (p40) and thyroid transcription factor-1 immunoreactivity on
small biopsies or cellblocks for typing non-small cell lung cancer:
a novel two-hit, sparing-material approach. J Thorac Oncol.
7:281–290. 2012. View Article : Google Scholar
|
|
28
|
Kogure Y, Ando M, Saka H, et al: Histology
and smoking status predict survival of patients with advanced
non-small-cell lung cancer. Results of West Japan Oncology Group
(WJOG) Study 3906L. J Thorac Oncol. 8:753–758. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cipriano R, Bryson BL, Miskimen KL, et al:
Hyperactivation of EGFR and downstream effector phospholipase D1 by
oncogenic FAM83B. Oncogene. 33:3298–3306. 2014. View Article : Google Scholar :
|
|
30
|
Cipriano R, Miskimen KL, Bryson BL, Foy
CR, Bartel CA and Jackson MW: FAM83B-mediated activation of
PI3K/AKT and MAPK signaling cooperates to promote epithelial cell
transformation and resistance to targeted therapies. Oncotarget.
4:729–738. 2013.PubMed/NCBI
|
|
31
|
Bass AJ, Watanabe H, Mermel CH, et al:
SOX2 is an amplified lineage-survival oncogene in lung and
esophageal squamous cell carcinomas. Nat Genet. 41:1238–1242. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hussenet T, Dali S, Exinger J, et al: SOX2
is an oncogene activated by recurrent 3q26.3 amplifications in
human lung squamous cell carcinomas. PLoS One. 5:e89602010.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wilbertz T, Wagner P, Petersen K, et al:
SOX2 gene amplification and protein overexpression are associated
with better outcome in squamous cell lung cancer. Mod Pathol.
24:944–953. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hilger M and Mann M: Triple SILAC to
determine stimulus specific interactions in the Wnt pathway. J
Proteome Res. 11:982–994. 2012. View Article : Google Scholar :
|
